985P - Prognostic implication of ERCC-1 protein expression in resected head and neck cancer

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Head and Neck Cancers
Presenter Yoon Ho Ko
Citation Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376
Authors Y.H. Ko1, H.J. An2, C.K. Jung3, J.H. Kang4, M.S. Kim5, K.J. Cho6, H.S. Won1, D.S. Sun1
  • 1Medical Oncology, Uijeongbu St. Mary's hospital Catholic University, 480-717 - Uijeongbu-si/KR
  • 2Medical Oncology, Suwon St. Vincent's hospital Catholic University, 442-723 - Suwon/KR
  • 3Hospital Pathology, Seoul St. Mary's hospital Catholic University, 137-701 - Seoel/KR
  • 4Medical Oncology, Seoul St. Mary's hospital Catholic University, 137-701 - Seoel/KR
  • 5Surgical Oncology, Seoul St. Mary's hospital Catholic University, 137-701 - Seoel/KR
  • 6Surgical Oncology, Uijeongbu St. Mary's hospital Catholic University, 480-717 - Uijeongbu-si/KR

Abstract

Background

The excision repair cross-complement group 1 (ERCC1) expression is related to prognosis and sensitivity to platinum-based chemotherapy in various cancers, especially lung. Platinum is the most frequently chemotherapeutic used in treatment of squamous cell carcinoma of the head and neck cancer (SCCHN), and ERCC1 has been studied as a predictive biomarker of cisplatin-containing chemo or chemo-radiotherapy. In this study, we assessed the prognostic role of ERCC1 protein expression in surgically resected SCCHN.

Methods

Between 1994 and 2012, 204 patients who were diagnosed with oropharynx or oral cavity cancer and underwent curative surgical resection were included. ERCC1 protein expression was evaluated by immunohistochemistry. Clinical and pathologic records were retrospectively reviewed.

Results

ERCC1 protein was positive in 136 (66.7%) patients. High ERCC1 expression was associated with oral cavity cancer (P 

Conclusions

ERCC1 protein expression can help to predict prognosis in surgically resected oropharynx or oral cavity SCCHN, especially in advanced stage.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

The Catholic University of Korea

Disclosure

All authors have declared no conflicts of interest.